Eli Lilly Stock Falls 2% on GLP-1 Data

Eli Lilly shares slipped 2% after weekly prescription data showed mixed performance across its GLP-1 portfolio.
Mounjaro prescriptions rose to ~758,400 total and 367,900 new, while Zepbound fell to 615,300 total and 350,600 new versus prior week.
Combined GLP-1 prescriptions slipped 0.3% to 1,503,100, with the franchise holding roughly 59% new‑prescription market share unchanged.
New drug Foundayo, launched April 9, logged ~3,700 prescriptions in week two, far below oral Wegovy’s ~18,400 in its second week.